Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board
Codexis (NASDAQ: CDXS) has appointed Arthur Levin, PhD to its Strategic Advisory Board. Dr. Levin, a founding member of Avidity Biosciences and current board member, brings three decades of oligonucleotide development experience to support Codexis's ECO Synthesis™ manufacturing platform growth.
Dr. Levin's extensive background includes being the first to develop approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials. He previously served as Distinguished Scientist, Strategic Leader, and Chief Scientific Officer at Avidity, and held senior development roles at miRagen Therapeutics, Ionis Pharmaceuticals, and Santaris Pharmaceuticals.
With over 100 scientific publications and several highly-cited reviews in the field, Dr. Levin will provide strategic guidance to Codexis as it expands its RNAi therapeutics capabilities through enzymatic technologies.
Codexis (NASDAQ: CDXS) ha nominato Arthur Levin, PhD nel suo Consiglio Consultivo Strategico. Il Dr. Levin, membro fondatore di Avidity Biosciences e attuale membro del consiglio, porta con sé tre decenni di esperienza nello sviluppo di oligonucleotidi per supportare la crescita della piattaforma produttiva ECO Synthesis™ di Codexis.
Il vasto background del Dr. Levin include il fatto di essere stato il primo a sviluppare farmaci antisenso approvati e il primo terapeuta mirato al microRNA in sperimentazione clinica. Ha precedentemente ricoperto incarichi come Scienziato Distinto, Leader Strategico e Direttore Scientifico presso Avidity, e ha avuto ruoli di sviluppo senior presso miRagen Therapeutics, Ionis Pharmaceuticals e Santaris Pharmaceuticals.
Con oltre 100 pubblicazioni scientifiche e diverse recensioni altamente citate nel campo, il Dr. Levin fornirà indicazioni strategiche a Codexis mentre espande le sue capacità terapeutiche RNAi tramite tecnologie enzimatiche.
Codexis (NASDAQ: CDXS) ha nombrado a Arthur Levin, PhD en su Junta Asesora Estratégica. El Dr. Levin, miembro fundador de Avidity Biosciences y actual miembro de la junta, aporta tres décadas de experiencia en el desarrollo de oligonucleótidos para apoyar el crecimiento de la plataforma de fabricación ECO Synthesis™ de Codexis.
El amplio trasfondo del Dr. Levin incluye ser el primero en desarrollar medicamentos anticon sentido aprobados y el primer terapéutico dirigido a microARN en ensayos clínicos. Anteriormente, se desempeñó como Científico Distinguido, Líder Estratégico y Director Científico en Avidity, y ocupó roles de desarrollo senior en miRagen Therapeutics, Ionis Pharmaceuticals y Santaris Pharmaceuticals.
Con más de 100 publicaciones científicas y varias revisiones altamente citadas en el campo, el Dr. Levin proporcionará orientación estratégica a Codexis a medida que expande sus capacidades terapéuticas de RNAi a través de tecnologías enzimáticas.
Codexis (NASDAQ: CDXS)는 Arthur Levin, PhD를 전략 자문 위원회에 임명했습니다. Levin 박사는 Avidity Biosciences의 창립 멤버이자 현재 이사로서 Codexis의 ECO Synthesis™ 제조 플랫폼의 성장을 지원하기 위해 30년 이상의 올리고뉴클레타이드 개발 경험을 가지고 있습니다.
Levin 박사는 승인된 항센스 약물을 처음으로 개발한 사람이며, 임상 시험에서 첫 번째로 microRNA를 목표로 한 치료제를 개발한 경험을 가지고 있습니다. 그는 Avidity에서 저명한 과학자, 전략 리더, 최고 과학 책임자로 근무했으며, miRagen Therapeutics, Ionis Pharmaceuticals 및 Santaris Pharmaceuticals에서 고위 개발 역할을 수행했습니다.
100편 이상의 과학 논문과 여러 차트에서 인용된 리뷰가 있는 Levin 박사는 Codexis가 효소 기술을 통해 RNAi 치료 능력을 확장하는 데 전략적 지침을 제공할 것입니다.
Codexis (NASDAQ: CDXS) a nommé Arthur Levin, PhD dans son Conseil Consultatif Stratégique. Le Dr Levin, membre fondateur d'Avidity Biosciences et membre actuel du conseil, apporte trois décennies d'expérience dans le développement d'oligonucleotides pour soutenir la croissance de la plateforme de fabrication ECO Synthesis™ de Codexis.
Le parcours étendu du Dr Levin comprend le fait d'avoir été le premier à développer des médicaments anti-sens approuvés et le premier thérapeutique ciblé microARN dans les essais cliniques. Il a précédemment occupé les postes de scientifique distingué, de leader stratégique et de directeur scientifique chez Avidity, et a occupé des rôles de développement senior chez miRagen Therapeutics, Ionis Pharmaceuticals et Santaris Pharmaceuticals.
Avec plus de 100 publications scientifiques et plusieurs revues très citées dans le domaine, le Dr Levin fournira des conseils stratégiques à Codexis alors que l'entreprise développe ses capacités thérapeutiques en RNAi grâce aux technologies enzymatiques.
Codexis (NASDAQ: CDXS) hat Arthur Levin, PhD in sein Strategisches Beratungsgremium berufen. Dr. Levin, ein Gründungsmitglied von Avidity Biosciences und aktuelles Mitglied des Vorstands, bringt drei Jahrzehnte Erfahrung in der Entwicklung von Oligonukleotiden mit, um das Wachstum von Codexis' ECO Synthesis™-Herstellungsplattform zu unterstützen.
Der umfangreiche Hintergrund von Dr. Levin umfasst die Entwicklung der ersten genehmigten Antisense-Arzneimittel und des ersten therapeutischen Mittels, das in klinischen Studien gezielt auf microRNA abzielte. Zuvor war er als Distinguished Scientist, Strategic Leader und Chief Scientific Officer bei Avidity tätig und hatte leitende Entwicklungspositionen bei miRagen Therapeutics, Ionis Pharmaceuticals und Santaris Pharmaceuticals inne.
Mit über 100 wissenschaftlichen Veröffentlichungen und mehreren hochzitierten Übersichtsartikeln in diesem Bereich wird Dr. Levin Codexis strategische Anleitung geben, während das Unternehmen seine RNAi-Therapie-Fähigkeiten durch enzymatische Technologien ausbaut.
- Strategic addition of a highly experienced oligonucleotide expert to strengthen the ECO Synthesis platform development
- Appointment brings expertise from successful development of first-approved antisense drugs
- Enhanced capability to attract and onboard new customers for the ECO Synthesis platform
- None.
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company’s Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform.
“We are thrilled to have such a distinguished oligonucleotide leader as Art Levin join our SAB,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis. “With extensive experience in the development of numerous oligonucleotides, including the first approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials, Art will provide invaluable guidance as we continue on our growth trajectory with the ECO Synthesis platform.”
Dr. Levin added, “I am excited to partner with Codexis as it expands the possibility of RNAi therapeutics through its groundbreaking enzymatic technologies. As someone who has been in the oligonucleotide business for decades, it is exciting to see momentum for the space increasing so drastically. I look forward to working with the management team and SAB to help usher Codexis through this next phase of growth.”
In addition to his role on the Board of Directors, Dr. Levin previously held the positions of Distinguished Scientist, Strategic Leader and Chief Scientific Officer at Avidity. Dr. Levin is a highly regarded key opinion leader in the RNA therapeutics field who has led teams responsible for the development of many oligonucleotides. Prior to joining Avidity, Dr. Levin was the Executive Vice President of Research and Development at miRagen Therapeutics and held senior drug development roles at Ionis (formerly Isis) Pharmaceuticals and Santaris Pharmaceuticals. He has published more than 100 scientific articles and has authored several of the most cited reviews in the field. In addition to Codexis, he serves on the scientific advisory boards of multiple institutions. Dr. Levin received a doctorate in toxicology from the University of Rochester and holds a bachelor’s degree in biology from Muhlenberg College.
About the Codexis Strategic Advisory Board
Codexis’ Strategic Advisory Board (SAB) was established in 2023 and is comprised of experts across oligonucleotide synthesis, manufacturing and commercialization. The SAB plays a pivotal role in guiding the Company’s strategic direction and offers valuable insights to inform the continued development of the ECO Synthesis™ manufacturing platform. Current members include John Maraganore, PhD, founder and former Chief Executive Officer of Alnylam Pharmaceuticals; Masad Damha, PhD, Distinguished James McGill Professor at McGill University; Jim Lalonde, PhD, biotechnology consultant for start-up companies in enzyme engineering and former Senior Vice President of Research and Development at Codexis; and Carole Cobb, MBA, biotechnology consultant and former Chief Operating Officer at GreenLight Biosciences. More information about Codexis’ SAB can be found on the About Us section of the Company’s corporate website, located here.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “suggest,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management, including but not limited to statements regarding the potential of the ECO Synthesis™ platform, and it providing an opportunity for Codexis to efficiently capture meaningful market share. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; if any of its collaborators terminate their development programs under their respective license agreements with Codexis; Codexis may need additional capital in the future in order to expand its business; if Codexis is unable to successfully develop and commercialize new technology such as its ECO Synthesis™ platform and its dsRNA ligase; Codexis dependence on a limited number of products and customers, and potential adverse effects to Codexis’ business if its customers’ products are not received well in the markets; if competitors and potential competitors who have greater resources and experience than Codexis develop products and technologies that make Codexis’ products and technologies obsolete; if Codexis is unable to accurately forecast financial and operational performance; and market and economic conditions may negatively impact Codexis business, financial condition and share price. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2024 and in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on October 31, 2024, including under the caption “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/e3137aaa-14c6-4e44-b71a-cb4b8bc4e4cb
FAQ
What is the significance of Arthur Levin joining Codexis (CDXS) Strategic Advisory Board?
How will Dr. Levin's appointment impact Codexis (CDXS) ECO Synthesis platform?
What is Dr. Levin's experience in RNA therapeutics before joining CDXS?
How does CDXS plan to leverage Dr. Levin's expertise in oligonucleotide development?
